

Please complete the ABSTRACT TEMPLATE online, for Biomed 2023 Company Presentations
ABSTRACT TEMPLATE: CHECKLIST AND INSTRUCTIONS Company name Genetika+ * Website
<https://www.genetikaplus.com> * CEO name Talia Cohen Solal * Select a CATEGORY: Biotech/Pharma
Select up to two SESSIONS per abstract from the list below * 2. Do we Know Enough About the Brain
to Treat Neurological Disorders? 5. AI tapestry: optimizing the interaction of AI and Biopharma o
Executive Summary / Investment Rational Genetika+ is transforming care for psychiatric and
neurological diseases by combining stem-cell technology, genomics and AI for treatment
optimization and effective drug development. In the US alone, tackling depression represents a
market of \$6B, and with other CNS indications, a potential US market of \$22B. We are currently
focused on our ongoing pharma partnership and launching our first commercial product. o Core
Technology Our “brain in a dish” technology requires only a simple blood test to determine which
antidepressant treatment is best suited for a patient using our innovative stem cell technology. We
are able to combine this unique technology with patient genetics and patient history, bringing the
predictive power of our platform to an unprecedented 79.3% accuracy. o Product Profile/Pipeline We
are finalizing the operational capacity of our US laboratory to initiate commercial sales of our clinical
test by the end of 2023. We have an ongoing partnership with an unpublished pharma company
focused on preclinical drug development for major depressive disorder. Lab capacity will increase
starting in 2024 to support increased test sales and to meet drug development milestones. o
Business Strategy Our business model is split between clinical lab tests and pharma partnerships.
Part one is focused on penetrating the market with our clinical lab test, which in turn, further
develops our data asset and biobank for patient stratification. In part two, the data asset will be used
to generate efficiencies and improve success rates in drug development via pharma partnerships. o
What's Next? We are currently in negotiations with additional pharma companies and telemedicine
platforms/employer customers for commercial partnerships. We are investing in R&D to improve the
quality and precision of our platform. We have ongoing clinical trials in the US/Israel while working to
develop a larger RCT. We are also targeting new indications, planning clinical trials for Alzheimer's
and Schizophrenia in 2025.